# EDGAR Filing Document

**Accession Number:** 0001782223
**File Stem:** 0000078003-23-000053
**Filing Date:** 2023-3
**Character Count:** 17377
**Document Hash:** ba77ff037650af9214e1128b2a11fb86
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000078003-23-000053.hdr.sgml**: 20230323

**ACCESSION NUMBER**: 0000078003-23-000053

**CONFORMED SUBMISSION TYPE**: SC 13G/A

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20230323

**DATE AS OF CHANGE**: 20230323

**GROUP MEMBERS**: PFIZER VENTURES (US) LLC

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Pyxis Oncology, Inc.
- **CENTRAL INDEX KEY:** 0001782223
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 831160910
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC 13G/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-92951
- **FILM NUMBER:** 23756501

**BUSINESS ADDRESS:**
- **STREET 1:** 35 CAMBRIDGE PARK DRIVE
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02140
- **BUSINESS PHONE:** (617) 221-9059

**MAIL ADDRESS:**
- **STREET 1:** 35 CAMBRIDGE PARK DRIVE
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02140
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** PFIZER INC
- **CENTRAL INDEX KEY:** 0000078003
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 135315170
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC 13G/A

**BUSINESS ADDRESS:**
- **STREET 1:** 66 HUDSON BOULEVARD EAST
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10001-2192
- **BUSINESS PHONE:** 2127332323

**MAIL ADDRESS:**
- **STREET 1:** 66 HUDSON BOULEVARD EAST
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10001-2192

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** PFIZER CHARLES & CO INC
- **DATE OF NAME CHANGE:** 19710908

CUSIP No. 747324101

---

| |
|:---|
| SECURITIES AND EXCHANGE COMMISSION |
| Washington, D.C. 20549 |
| SCHEDULE 13G |
| (Rule 13d-102) |
| INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT |
| TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED |
| PURSUANT TO RULE 13d-2(b) |
| (Amendment No. 2) <sup>1</sup> |
| Pyxis Oncology, Inc. |
| (Name of Issuer) |
| Common Stock, $0.001 par value |
| (Title of Class of Securities) |
| 747324101 |
| (CUSIP Number) |
| March 17, 2023 |
| (Date of Event Which Requires Filing of this Statement) |

---

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

[ ] Rule 13d-1(b)

[ ] Rule 13d-1(c)

[X] Rule 13d-1(d)&nbsp;&nbsp;&nbsp;&nbsp;

<br>__________

1 The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.

Page **1** of **8**

------

CUSIP No. 747324101

---

| | | | | |
|:---|:---|:---|:---|:---|
| 1. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NAME OF REPORTING PERSON<br>S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (VOLUNTARY)<br>Pfizer Inc. 13-5315170 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NAME OF REPORTING PERSON<br>S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (VOLUNTARY)<br>Pfizer Inc. 13-5315170 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NAME OF REPORTING PERSON<br>S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (VOLUNTARY)<br>Pfizer Inc. 13-5315170 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NAME OF REPORTING PERSON<br>S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (VOLUNTARY)<br>Pfizer Inc. 13-5315170 |
| 2. | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) [ ]<br>(b) [ ] |
| 3. | SEC USE ONLY | SEC USE ONLY | SEC USE ONLY | SEC USE ONLY |
| 4. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CITIZENSHIP OR PLACE OF ORGANIZATION<br>Delaware | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CITIZENSHIP OR PLACE OF ORGANIZATION<br>Delaware | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CITIZENSHIP OR PLACE OF ORGANIZATION<br>Delaware | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CITIZENSHIP OR PLACE OF ORGANIZATION<br>Delaware |
| NUMBER OF <br>SHARES <br>BENEFICIALLY <br>OWNED BY <br>EACH <br>REPORTING <br>PERSON <br>WITH | NUMBER OF <br>SHARES <br>BENEFICIALLY <br>OWNED BY <br>EACH <br>REPORTING <br>PERSON <br>WITH | 5. | SOLE VOTING POWER 5,952,263 shares of Common Stock, $0.001 par value per share ("Common Stock") | SOLE VOTING POWER 5,952,263 shares of Common Stock, $0.001 par value per share ("Common Stock") |
| NUMBER OF <br>SHARES <br>BENEFICIALLY <br>OWNED BY <br>EACH <br>REPORTING <br>PERSON <br>WITH | NUMBER OF <br>SHARES <br>BENEFICIALLY <br>OWNED BY <br>EACH <br>REPORTING <br>PERSON <br>WITH | 6. | SHARED VOTING POWER 1,080,507 shares of Common Stock, held by Pfizer Ventures (US) LLC, a wholly-owned subsidiary of Pfizer Inc. | SHARED VOTING POWER 1,080,507 shares of Common Stock, held by Pfizer Ventures (US) LLC, a wholly-owned subsidiary of Pfizer Inc. |
| NUMBER OF <br>SHARES <br>BENEFICIALLY <br>OWNED BY <br>EACH <br>REPORTING <br>PERSON <br>WITH | NUMBER OF <br>SHARES <br>BENEFICIALLY <br>OWNED BY <br>EACH <br>REPORTING <br>PERSON <br>WITH | 7. | SOLE DISPOSITIVE POWER 5,952,263 shares of Common Stock | SOLE DISPOSITIVE POWER 5,952,263 shares of Common Stock |
| NUMBER OF <br>SHARES <br>BENEFICIALLY <br>OWNED BY <br>EACH <br>REPORTING <br>PERSON <br>WITH | NUMBER OF <br>SHARES <br>BENEFICIALLY <br>OWNED BY <br>EACH <br>REPORTING <br>PERSON <br>WITH | 8. | SHARED DISPOSITIVE POWER 1,080,507 shares of Common Stock held directly by Pfizer Ventures (US) LLC, a wholly-owned subsidiary of Pfizer Inc. | SHARED DISPOSITIVE POWER 1,080,507 shares of Common Stock held directly by Pfizer Ventures (US) LLC, a wholly-owned subsidiary of Pfizer Inc. |
| 9. | AGGREGATE AMOUNT BENEFICIALLY OWNED <br>BY EACH REPORTING PERSON 7,032,770\* | AGGREGATE AMOUNT BENEFICIALLY OWNED <br>BY EACH REPORTING PERSON 7,032,770\* | AGGREGATE AMOUNT BENEFICIALLY OWNED <br>BY EACH REPORTING PERSON 7,032,770\* | AGGREGATE AMOUNT BENEFICIALLY OWNED <br>BY EACH REPORTING PERSON 7,032,770\* |
| 10. | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES | <br> [ ] |
| 11. | &nbsp;&nbsp;PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 19.02\*\* | &nbsp;&nbsp;PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 19.02\*\* | &nbsp;&nbsp;PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 19.02\*\* | &nbsp;&nbsp;PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 19.02\*\* |
| 12. | &nbsp;&nbsp;TYPE OF REPORTING PERSON CO | &nbsp;&nbsp;TYPE OF REPORTING PERSON CO | &nbsp;&nbsp;TYPE OF REPORTING PERSON CO | &nbsp;&nbsp;TYPE OF REPORTING PERSON CO |

---

\*Includes 1,080,507 shares held directly by Pfizer Ventures (US) LLC. Pfizer Inc. may be deemed to have beneficial ownership over such shares since Pfizer Ventures (US) LLC is a wholly-owned subsidiary of Pfizer Inc.

\*\*The percentages used herein are based on 36,980,621 shares of Common Stock outstanding as of March 21, 2023, as set forth in the Issuer's Form 10-K that was filed with the Securities and Exchange Commission on March 22, 2023

Page **2** of **8**

------

CUSIP No. 747324101

---

| | | | | |
|:---|:---|:---|:---|:---|
| 1. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NAME OF REPORTING PERSON<br>S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (VOLUNTARY)<br>Pfizer Ventures (US) LLC 82-5524518  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NAME OF REPORTING PERSON<br>S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (VOLUNTARY)<br>Pfizer Ventures (US) LLC 82-5524518  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NAME OF REPORTING PERSON<br>S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (VOLUNTARY)<br>Pfizer Ventures (US) LLC 82-5524518  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NAME OF REPORTING PERSON<br>S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (VOLUNTARY)<br>Pfizer Ventures (US) LLC 82-5524518  |
| 2. | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) [ ]<br>(b) [ ] |
| 3. | SEC USE ONLY | SEC USE ONLY | SEC USE ONLY | SEC USE ONLY |
| 4. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CITIZENSHIP OR PLACE OF ORGANIZATION<br>Delaware | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CITIZENSHIP OR PLACE OF ORGANIZATION<br>Delaware | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CITIZENSHIP OR PLACE OF ORGANIZATION<br>Delaware | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CITIZENSHIP OR PLACE OF ORGANIZATION<br>Delaware |
| NUMBER OF <br>SHARES <br>BENEFICIALLY <br>OWNED BY <br>EACH <br>REPORTING <br>PERSON <br>WITH | NUMBER OF <br>SHARES <br>BENEFICIALLY <br>OWNED BY <br>EACH <br>REPORTING <br>PERSON <br>WITH | 5. | &nbsp;&nbsp;SOLE VOTING POWER -0- | &nbsp;&nbsp;SOLE VOTING POWER -0- |
| NUMBER OF <br>SHARES <br>BENEFICIALLY <br>OWNED BY <br>EACH <br>REPORTING <br>PERSON <br>WITH | NUMBER OF <br>SHARES <br>BENEFICIALLY <br>OWNED BY <br>EACH <br>REPORTING <br>PERSON <br>WITH | 6. | &nbsp;&nbsp;SHARED VOTING POWER 1,080,507 shares of Common Stock | &nbsp;&nbsp;SHARED VOTING POWER 1,080,507 shares of Common Stock |
| NUMBER OF <br>SHARES <br>BENEFICIALLY <br>OWNED BY <br>EACH <br>REPORTING <br>PERSON <br>WITH | NUMBER OF <br>SHARES <br>BENEFICIALLY <br>OWNED BY <br>EACH <br>REPORTING <br>PERSON <br>WITH | 7. | &nbsp;&nbsp;SOLE DISPOSITIVE POWER -0- | &nbsp;&nbsp;SOLE DISPOSITIVE POWER -0- |
| NUMBER OF <br>SHARES <br>BENEFICIALLY <br>OWNED BY <br>EACH <br>REPORTING <br>PERSON <br>WITH | NUMBER OF <br>SHARES <br>BENEFICIALLY <br>OWNED BY <br>EACH <br>REPORTING <br>PERSON <br>WITH | 8. | &nbsp;&nbsp;SHARED DISPOSITIVE POWER 1,080,507 shares of Common Stock | &nbsp;&nbsp;SHARED DISPOSITIVE POWER 1,080,507 shares of Common Stock |
| 9. | AGGREGATE AMOUNT BENEFICIALLY OWNED <br>BY EACH REPORTING PERSON 1,080,507 shares of Common Stock held directly by Pfizer Ventures (US) LLC, a wholly-owned subsidiary of Pfizer Inc. | AGGREGATE AMOUNT BENEFICIALLY OWNED <br>BY EACH REPORTING PERSON 1,080,507 shares of Common Stock held directly by Pfizer Ventures (US) LLC, a wholly-owned subsidiary of Pfizer Inc. | AGGREGATE AMOUNT BENEFICIALLY OWNED <br>BY EACH REPORTING PERSON 1,080,507 shares of Common Stock held directly by Pfizer Ventures (US) LLC, a wholly-owned subsidiary of Pfizer Inc. | AGGREGATE AMOUNT BENEFICIALLY OWNED <br>BY EACH REPORTING PERSON 1,080,507 shares of Common Stock held directly by Pfizer Ventures (US) LLC, a wholly-owned subsidiary of Pfizer Inc. |
| 10. | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES | <br> [ ] |
| 11. | &nbsp;&nbsp;PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 2.92%\*\* | &nbsp;&nbsp;PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 2.92%\*\* | &nbsp;&nbsp;PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 2.92%\*\* | &nbsp;&nbsp;PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 2.92%\*\* |
| 12. | &nbsp;&nbsp;TYPE OF REPORTING PERSON OO | &nbsp;&nbsp;TYPE OF REPORTING PERSON OO | &nbsp;&nbsp;TYPE OF REPORTING PERSON OO | &nbsp;&nbsp;TYPE OF REPORTING PERSON OO |

---

\*\*The percentages used herein are based on 36,980,621 shares of Common Stock outstanding as of March 21, 2023, as set forth in the Issuer's Form 10-K that was filed with the Securities and Exchange Commission on March 22, 2023.

Page **3** of **8**

------

CUSIP No. 747324101

<u>SCHEDULE 13G</u>

---

| | |
|:---|:---|
| ITEM 1(a) | NAME OF ISSUER: Pyxis Oncology, Inc. (the "Issuer"). |
| ITEM 1(b) | ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES: |
|  | 35 Cambridge Park Drive , Cambridge, MA 02140 |
| ITEM 2(a) | NAME OF PERSON FILING: |
|  | Pfizer Inc. ("Pfizer")<br>Pfizer Ventures (US) LLC ("PVUS")<br>PVUS is a wholly-owned subsidiary of Pfizer. The Joint Filing Agreement between Pfizer and PVUS is filed herewith as Exhibit 99.1. |
| ITEM 2(b) | ADDRESS OF PRINCIPAL BUSINESS OFFICE: |
|  | Pfizer and PVUS: 66 Hudson Boulevard East, New York, NY 10001-2192 |
| ITEM 2(c) | CITIZENSHIP: |
|  | Pfizer and PVUS: Delaware |
| ITEM 2(d) | TITLE OF CLASS OF SECURITIES: |
|  | Common Stock, $0.001 par value |
| ITEM 2(e) | CUSIP NUMBER: 747324101 |
| ITEM 3 | IF THIS STATEMENT IS FILED PURSUANT TO §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: |
|  | Not applicable. |

---

(a) Broker or dealer registered under section 15 of the Act (15 U.S.C. 78os). <br>(b) Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c). <br>(c) Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c). <br>(d) Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

Page **4** of **8**

------

CUSIP No. 747324101

<br>(e) An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E). <br>(f) An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F). <br>(g) A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G). <br>(h) A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813). <br>(i) A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3). <br>(j) A non-US institution, in accordance with §240.13d-1(b)(1)(ii)(J); <br>(k) Group, in accordance with §230.405 240.13d-1(b)(1)(ii)(K). <br>If filing as a non-US institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: Not applicable.

Page **5** of **8**

------

CUSIP No. 747324101

---

| | | |
|:---|:---|:---|
| ITEM 4 | OWNERSHIP: | OWNERSHIP: |
| | The information requested in this item is incorporated herein by reference to rows 5 through 11 of the respective cover pages of Pfizer and PVUS to this Schedule 13G. | The information requested in this item is incorporated herein by reference to rows 5 through 11 of the respective cover pages of Pfizer and PVUS to this Schedule 13G. |
| ITEM 5 | OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS: | OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS: |
| | Not applicable. | Not applicable. |
| ITEM 6 | OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON: | OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON: |
| | Not applicable. | Not applicable. |
| ITEM 7 | IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT COMPANY: | IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT COMPANY: |
| | Not applicable. | Not applicable. |
| ITEM 8 | ITEM 8 | IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP: |
| | | Not applicable. |
| ITEM 9 | ITEM 9 | NOTICE OF DISSOLUTION OF GROUP: |
| | | Not applicable. |
| ITEM 10 | ITEM 10 | CERTIFICATION: |
| | | Not applicable. |

---

Page **6** of **8**

------

CUSIP No. 747324101

EXHIBIT INDEX

Exhibit Description

99.1 Joint Filing Agreement, dated as of March 23, 2023, by and between Pfizer and PVUS.

Page **7** of **8**

------

CUSIP No. 747324101

SIGNATURE

After reasonable inquiry and to the best of their knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

Dated: March 23, 2023

---

| | |
|:---|:---|
| PFIZER INC. | PFIZER INC. |
| By: | /s/ Susan Grant |
| Name: | Susan Grant |
| Title: | Assistant Secretary |
| PFIZER VENTURES (US) LLC | PFIZER VENTURES (US) LLC |
| By: | /s/ Susan Grant |
| Name: | Susan Grant |
| Title: | Secretary |

---

Page **8** of **8**

## Exhibit 99.1

CUSIP No. 747324101

Exhibit 99.1

JOINT FILING AGREEMENT

The undersigned hereby agree that the amendment to the statement on Schedule 13G to which this Agreement is annexed as Exhibit 99.1, including subsequent amendments thereto, is filed on behalf of each of them in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended.

Dated: March 23, 2023

---

| | |
|:---|:---|
| PFIZER INC. | PFIZER INC. |
| By: | /s/ Susan Grant |
| Name: | Susan Grant |
| Title: | Assistant Secretary |
| PFIZER VENTURES (US) LLC | PFIZER VENTURES (US) LLC |
| By: | /s/ Susan Grant |
| Name: | Susan Grant |
| Title: | Secretary |

---

<br>